

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5945236

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ROCHE GLYCART AG	12/14/2016
RECEIVING PARTY DATA		
Name:	F. Hoffmann-La Roche AG	
Street Address:	124 Grenzacherstrasse	
City:	Basle	
State/Country:	SWITZERLAND	
Postal Code:	CH-4070	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	15399122
CORRESPONDENCE DATA		
Fax Number:	(650)952-9881	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(650) 467-04795	
Email:	joanlm@gene.com	
Correspondent Name:	GREGORY M. ZINKL	
Address Line 1:	1 DNA WAY	
Address Line 4:	SOUTH SAN FRANCISCO, CALIFORNIA 94080-4990	
ATTORNEY DOCKET NUMBER:	P33335-US	
NAME OF SUBMITTER:	GREGORY M. ZINKL	
SIGNATURE:	/Gregory M. Zinkl/	
DATE SIGNED:	02/04/2020	
Total Attachments: 2		
source=33335 Assignment _Glycart to FHLR _#page1.tif		
source=33335 Assignment _Glycart to FHLR _#page2.tif		

ASSIGNMENT AGREEMENT

Roche Glycart AG ("ASSIGNOR") a corporation duly organized under the laws of Switzerland and having its principal place of business at Wagistrasse 18, CH-8952 Schlieren, Switzerland

acknowledges the previous transfer to

F. Hoffmann-La Roche AG ("ASSIGNEE") a corporation duly organized under the laws of Switzerland, and having its principal place of business at 124 Grenzacherstrasse, CH-4070 Basle, Switzerland

for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, of all right, title, and interest in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below for all countries of the world by operation of law, contract, or otherwise, and any Letters Patent which may hereafter be granted on the same in all countries of the world including any application claiming priority, divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof.

As far as the right, title, and interest of ASSIGNOR in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below may not have been transferred, for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers to ASSIGNEE, and to ASSIGNEE'S successors and assigns, for all countries of the world all of ASSIGNOR'S right, title and interest in, to, and deriving from the invention(s) described in the patent application(s) listed below, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, or other patent applications claiming the benefit of the filing date of the following patent application(s):


Case No.	Country	Filing Date	Serial No.
P33335-EP	Europe	8 January 2016	16150506.0

entitled

METHODS OF TREATING CEA-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-CEA/ANTI-CD3 BISPECIFIC ANTIBODIES

ASSIGNEE, by virtue of this Assignment, shall have the right to file and own patent applications that claim priority to and are based in whole or in part on the patent application(s) cited above in all countries of the world and to own Letters Patents that issue thereon. Accordingly, ASSIGNOR hereby authorizes and requests the patent offices to issue any Letters Patent which may issue for such patent applications, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, to ASSIGNEE, its successors and assigns.

ASSIGNOR does hereby covenant and agree with ASSIGNEE, its successors and assigns, that ASSIGNOR will not execute any writing or do any act conflicting with this assignment, and ASSIGNOR further agrees that he will, without charge to said ASSIGNEE, but at ASSIGNEE'S expense, cooperate with ASSIGNEE in the prosecution of said Letters Patent and/or applications, execute, verify, acknowledge and deliver all such further papers, including applications for Letters Patent and for the reissue thereof, and instruments of assignment and transfer thereof, and will perform such other acts as ASSIGNEE lawfully may request, to obtain or maintain Letters Patent for said invention and improvement in any and all countries, and to vest title thereto in said ASSIGNEE, or ASSIGNEE'S successors and assigns.



PATENT


REEL: 051713 FRAME: 0496

This agreement shall be governed and construed in accordance with substantive laws of Switzerland, with the exclusion of the Vienna Convention on the International Sale of Goods dated April 11, 1980. The competent courts of Basel City, Switzerland shall have exclusive jurisdiction.


ASSIGNOR**Roche Glycart AG**

Basel, Switzerland, December 14, 2016

Place, Date



Peter Küng




Susanne Amann

both duly authorized signatures

ASSIGNEE**F. Hoffmann-La Roche AG**


Basel, Switzerland, December 14, 2016

Place, Date



Thomas Winkler

Holder of procuration



Funda Iskender

Mandatory

Legalization

The undersigned Notary Public of the Canton of Basel-Stadt (Switzerland), Dr. Christoph Nertz, herewith legalizes the foregoing signature of

Roche Glycart AG, a stock company with legal domicile in Schlieren (Switzerland), rendered by

Mister Dr. Peter Küng, citizen of Eriswil (Switzerland), residing in Aillschwil (Switzerland), and

Miss Susanne Amann, German citizen, residing in Heitersheim (Germany),

both duly entitled to sign documents wherein property of the company is alienated.

He also legalizes the foregoing signature of

F. Hoffmann-La Roche AG, a stock company with legal domicile in Basel (Switzerland), rendered by

Mister Dr. Thomas Winkler, German citizen, residing in Riehen (Switzerland), and

Miss Funda Iskender, citizen of Pratteln (Switzerland), residing in Basel (Switzerland),


both duly entitled also to sign documents wherein property of the company is alienated.

All Signers and signatures personally known.

B a s e l (Switzerland), this 21st (twenty-first) day of December 2016 (two thousand and sixteen).



BR 1709/2016

**PATENT**